Literature DB >> 8633106

Alterations in the level of phosphotyrosine signal transduction constituents in human parotid tumors.

R Bu1, K R Purushotham, M Kerr, Z Tao, R Jonsson, J Olofsson, M G Humphreys-Beher.   

Abstract

Human parotid tumors were evaluated for the activation of the phosphotyrosine signaling pathway by Western blot, enzyme activity assay, and reverse transcriptase-polymerase chain reaction. Warthin's tumor and mucoepidermoid carcinomas had the greatest level of tyrosine phosphorylated proteins identified in plasma membrane fractions. These tumors, along with pleomorphic adenocarcinoma, showed high levels of membrane expression of the tyrosine kinase receptor, c-erbB-2, and phosphatidylinositol-3-kinase. Expression of the epidermal growth factor receptor was confined to normal tissue. The level of mRNA for c-erb was elevated only in mucoepidermoid carcinomas. Messenger RNA levels for ras were unchanged from control levels in all tumors, while the level of src mRNA was higher in the tumor samples than the normal parotid tissue. The activities of several signal transduction kinases, including protein kinase A and C were elevated in tumor tissue (7.7- to 18.9- and 0.4- to 3.7-fold higher, respectively), relative to surrounding normal tissue. While the level of glandular amylase was reduced (22%-0% of normal levels) in the tumor tissue, epidermal growth factor (EGF) and transforming growth factor-alpha (TGFalpha) content was dramatically higher in the neoplastic tissue (10- to 170-fold and 4.6- to 6.0-fold, respectively). These results suggest that with the presence of elevated levels of EGF, TGFalpha, and the oncoprotein receptor c-erbB-2 in the membrane of parotid tumors, cell proliferation and activation of the phosphotyrosine signal transduction pathway may involve autocrine stimulation through the expression of high levels of growth factor and receptor in the same tissue.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8633106     DOI: 10.3181/00379727-211-43969

Source DB:  PubMed          Journal:  Proc Soc Exp Biol Med        ISSN: 0037-9727


  4 in total

1.  Src-Induced cisplatin resistance mediated by cell-to-cell communication.

Authors:  Elizabeth Peterson-Roth; Cathleen M Brdlik; Peter M Glazer
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

2.  Immunohistochemical expression of the oncogenic molecules active Stat3 and survivin in benign and malignant salivary gland tumors.

Authors:  Nikolaos G Nikitakis; Mark A Scheper; Vasileios S Papanikolaou; Alexandra Sklavounou; John J Sauk
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2009-03-09

Review 3.  The role of Src in solid tumors.

Authors:  Deric L Wheeler; Mari Iida; Emily F Dunn
Journal:  Oncologist       Date:  2009-07-06

4.  Gap junction enhancer increases efficacy of cisplatin to attenuate mammary tumor growth.

Authors:  Stephanie N Shishido; Thu A Nguyen
Journal:  PLoS One       Date:  2012-09-13       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.